7th Annual BMRP Investigator Meeting - Abstract

Paul Terry^1,a, Shanti Sitaraman², Jerome Abramson¹, Sharon Pritchett¹ and Jack Mandel<sup>1,3

1</sup>Department of Epidemiology, Rollins School of Public Health, Emory University (Atlanta, Georgia, U.S.A.);²Divisionof Digestive Diseases, School of Medicine, Emory University (Atlanta, Georgia, U.S.A.); ³Dalla Lana School of Public Health, University of Toronto (Canada)

 

Physiologic data suggest that melatonin is important in GI tract physiology and health, and data from in vitro studies, animal experiments, and some studies in humans, suggest that supplemental melatonin may have an ameliorative effect on UC. Data from animal studies, the majority of case-reports, case-control studies of urinary 6-sulfatoxymelatonin (aMT6) levels, a follow-up study of shift-workers, and three clinical trials of melatonin and IBS have been encouraging, although there has been no formal clinical trial of melatonin supplementation and UC in humans. Given this background, we are conducting a pilot clinical trial of melatonin supplementation (in addition to standard therapy) of 5 mg/d versus placebo for 12 weeks in 60 patients with mild to moderate UC, as determined by Mayo Scores. 

  

^aPrincipal Investigator